Luvadaxistat (also known as TAK-831 and NBI-1065844) is a potent investigational DAAO inhibitor that was considered for the treatment of negative symptoms and is being developed for the treatment of cognitive impairment associated with schizophrenia (CIAS). Here, DAO is linked to schizophrenia.